跳至主要内容
临床试验/JPRN-UMIN000005952
JPRN-UMIN000005952已完成1 期

Phase I-II study of combination chemotherapy with Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancer - Phase I-II study of Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancer

Osaka university, faculty of medicine0 个研究点目标入组 40 人开始时间: 2011年7月8日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1)Patients who have a history of severe hypersensitivity to drug. 2)Patients with interstitial pneumonia. 3)Patients who have mmasive ascites and/or pleural effusion. 4)Patients who have severe infectious diseases. 5)Patients with other malignant disease. 6)Women at pregnant state or possibly pregnant women. 7)Patients with mental diseases. 8)Patients with symptomatic brain metastasis. 9)Patients with severe coronary disease. 10) Patients with uncontrollable diabetic disease. 11)Patients with watery diarrhea. 12)Patients with severe ileus. 13)Patients with intestinal bleeding. 14)Patients with positeve HBs antigen. 15)Patients with severe medical complications. 16)Patients with systematic edema. 17)Patients who are considered inappropriate for this study by the doctor.

研究者

发起方
Osaka university, faculty of medicine

相似试验